NCT00718419 is a Phase 2 clinical trial of Enzastaurin in Waldenstrom's Macroglobulinemia, sponsored by Eli Lilly and Company.

Who is sponsoring NCT00718419?

NCT00718419 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT00718419?

Interventions in NCT00718419: Enzastaurin.

What condition does NCT00718419 study?

NCT00718419 studies Waldenstrom's Macroglobulinemia, Multiple Myeloma.

Is NCT00718419 still recruiting?

NCT00718419 is currently completed. Last updated 1 September 2020.

Are results published for NCT00718419?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-09-01 · How we verify

NCT00718419

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma

Completed Phase 2 Results posted Last updated 1 September 2020

What this trial tests

Phase 2 trial testing Enzastaurin in Waldenstrom's Macroglobulinemia in 56 participants. Completed in 1 August 2012.

Timeline

1 July 2008

Primary endpoint
1 September 2010

1 August 2012

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	56
Start date	1 July 2008
Primary completion	1 September 2010
Estimated completion	1 August 2012
Sites	4 locations across United States, France

Drugs / interventions tested

Enzastaurin — full drug profile →

Conditions studied

Waldenstrom's Macroglobulinemia — all drugs for Waldenstrom's Macroglobulinemia →
Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

18 and older, any sex, with Waldenstrom's Macroglobulinemia or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate)
Time frame: Baseline to measured progressive disease up to 40.51 months
European Group for Blood and Bone Marrow Transplant (EBMT) Response Criteria (RC) used for MM. CR: no serum/urine M protein for 6 weeks (wk), \<5% plasma cells in bone marrow (PCBM), no lytic bone lesions (LBL) size/number increase, no soft tissue plasmacytomas (STPC); PR: met some CR criteria plus maintain for 6 wk ≥50% serum monoclonal paraprotein (SPEP) and PCBM decrease, either decrease of ≥90

Sponsor's own description

To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

p73 as a pharmaceutical target for cancer therapy.
Bisso A, Collavin L, Del Sal G. · · 2011 · cited 30× · PMID 21391908 · DOI 10.2174/138161211795222667
Kinase inhibitors as potential agents in the treatment of multiple myeloma.
Abramson HN. · · 2016 · cited 14× · PMID 27655636 · DOI 10.18632/oncotarget.10745
Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach.
Bai W, Wang H, Bai H. · · 2019 · cited 6× · PMID 32099441 · DOI 10.2147/pgpm.s228574

Verify or expand the search:

Other trials of Enzastaurin

Trials testing the same drug.

NCT00709995 — A Study for Participants With Metastatic Renal Cell Carcinoma · Phase 2 · completed

Other recruiting trials for Waldenstrom's Macroglobulinemia

Currently open trials in the same condition.

NCT00492050 — Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia · Phase 2 · active not recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00718419 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 1 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00718419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing